Deep Dive: GLP-1 vs. Dual Agonists

---

The Core Question

If semaglutide works so well — 15% average weight loss, major cardiovascular benefits, kidney protection — why does tirzepatide work even better? And what does the answer tell us about where this field is heading?

The short answer: tirzepatide doesn’t just stimulate GLP-1 receptors. It stimulates two receptor systems simultaneously — GLP-1 and GIP — and the combination produces effects that neither system achieves alone. Understanding why requires looking at what each receptor does, where they’re located in your body, and what happens when you activate both at once.

---

GLP-1: The System You Already Know

We covered GLP-1 (glucagon-like peptide-1) in the Deep Dive on Receptor Science in the Getting Started section. Here’s the quick recap:

What it is: A hormone your gut produces after you eat. It signals through GLP-1 receptors — a type of G-protein coupled receptor — found throughout your body.

Where the receptors are: GLP-1 receptors have been identified in the pancreas, brain (particularly the hypothalamus, brainstem, and area postrema), heart, blood vessels, kidneys, lungs, and gastrointestinal tract. That wide distribution is why GLP-1 medications affect so many systems beyond blood sugar.[1]

What GLP-1 receptor activation does:

Medications like semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide (Saxenda, Victoza) work by mimicking this hormone. They bind to GLP-1 receptors, activate the same pathways, but stick around far longer than natural GLP-1 — which is normally destroyed within minutes.

The clinical results are impressive. But they’re also the ceiling for a single-receptor approach. To go further, you need a second lever.

---

GIP: The Other Incretin

GIP — glucose-dependent insulinotropic polypeptide — is the less famous of the two “incretin” hormones. It was actually discovered before GLP-1, but it’s been historically overshadowed in drug development. That’s changing fast.

What it is: A hormone produced by K-cells in your small intestine, released in response to eating — particularly fats and carbohydrates. Together with GLP-1, GIP accounts for the “incretin effect”: the observation that eating food triggers far more insulin release than injecting the same amount of glucose directly into the bloodstream.[2]

Where the receptors are: GIP receptors (GIPR) are expressed in the pancreas (both alpha and beta cells), adipose tissue (fat cells), bone, brain (hypothalamus, brainstem, and hippocampus), and the gastrointestinal tract.

What GIP receptor activation does:

The GIP Paradox

Here’s the genuinely strange part: both GIP receptor agonists (activators) and GIP receptor antagonists (blockers) can cause weight loss. This seems contradictory — how can turning a receptor on AND turning it off both produce the same result?

The current leading theory involves what scientists call receptor desensitization. When you flood a receptor system with a sustained, high dose of its agonist (as tirzepatide does with GIP receptors), the initial response is activation — but prolonged exposure leads to downregulation. The receptors internalize, the signaling dampens, and the net effect at the tissue level can resemble what you’d see with a blocker.

In other words, chronic high-dose GIP agonism may functionally become GIP antagonism at certain tissues — particularly adipose tissue — while maintaining beneficial agonist effects in the brain and pancreas. This “biased agonism” (activation that favors some signaling pathways over others) may be part of why tirzepatide works so well for weight loss despite activating a receptor historically associated with fat storage.[4]

This is still an active area of research. The full picture isn’t settled. But it helps explain why “just blocking GIP” and “just activating GIP” both show weight loss effects in studies — the biology is more nuanced than on/off.

---

Tirzepatide: The Dual Agonist Blueprint

Tirzepatide (Mounjaro, Zepbound) is the first FDA-approved dual GLP-1/GIP receptor agonist. It was designed from the ground up to activate both receptor systems, but not equally.

Imbalanced and Biased

A 2020 study in the Journal of Clinical Investigation characterized tirzepatide’s pharmacology in precise terms: it is an “imbalanced and biased dual GIP and GLP-1 receptor agonist.”[4]

What does that mean?

Imbalanced: Tirzepatide binds to GIP receptors with roughly equal affinity to native GIP (the natural hormone). But it binds to GLP-1 receptors with about 5-fold lower affinity than native GLP-1. So it’s a strong GIP agonist and a moderate GLP-1 agonist — not 50/50.

Biased: At the GLP-1 receptor specifically, tirzepatide doesn’t activate all the same downstream signaling pathways that native GLP-1 does. It shows a bias toward cAMP signaling (the pathway most associated with insulin secretion) and reduced beta-arrestin recruitment (which is associated with receptor internalization and desensitization). This bias may explain why tirzepatide produces robust metabolic effects with a side effect profile that’s broadly similar to — rather than worse than — pure GLP-1 agonists, despite activating two receptor systems.

This is deliberate molecular engineering. Tirzepatide wasn’t created by simply stapling a GLP-1 drug and a GIP drug together. It’s a single 39-amino acid peptide designed to hit both targets with specific affinity and signaling biases.

---

Head-to-Head: The Clinical Evidence

Two landmark trials have directly compared tirzepatide against semaglutide — one for diabetes, one for obesity. Both showed tirzepatide outperforming semaglutide at their maximum respective doses.

SURPASS-2: Type 2 Diabetes

Published in the New England Journal of Medicine in 2021, SURPASS-2 randomized 1,879 patients with Type 2 diabetes to tirzepatide (5, 10, or 15 mg) vs. semaglutide 1 mg, all given weekly for 40 weeks.[5]

Blood sugar control (HbA1c reduction):

All three tirzepatide doses achieved statistically superior blood sugar reduction compared to semaglutide. At the highest dose, 97% of tirzepatide patients reached an HbA1c below 7%, and 62% reached below 5.7% (the non-diabetic range).

Weight loss:

At maximum dose, tirzepatide produced roughly twice the weight loss as semaglutide — in a diabetes trial where weight loss wasn’t even the primary endpoint.

Important caveat: SURPASS-2 compared tirzepatide at its max dose (15 mg) against semaglutide at 1 mg — not semaglutide’s max dose of 2 mg. The comparison wasn’t perfectly balanced. But even at lower tirzepatide doses, the results were at least as good as semaglutide.

SURMOUNT-5: Obesity (Head-to-Head)

Published in the New England Journal of Medicine in 2025, SURMOUNT-5 was the study the field had been waiting for — a direct head-to-head comparison for obesity treatment at maximum doses. It randomized 751 adults with obesity (without diabetes) to tirzepatide 10 or 15 mg vs. semaglutide 2.4 mg for 72 weeks.[6]

That’s 47% more weight loss with tirzepatide — a difference that was statistically significant and clinically meaningful.

The 25% threshold is particularly striking — more than a third of tirzepatide users lost at least a quarter of their body weight, compared to fewer than one in ten on semaglutide.

Side effects were similar between groups — mostly GI-related (nausea, diarrhea, constipation), with comparable discontinuation rates.

SURPASS-CVOT: Cardiovascular Outcomes

The cardiovascular outcomes story is also emerging. The SURPASS-CVOT trial — a head-to-head comparison of tirzepatide vs. dulaglutide (Trulicity) in over 13,000 patients with Type 2 diabetes and cardiovascular disease — has confirmed cardiovascular protection for tirzepatide, with superior outcomes compared to dulaglutide.[7]

This is significant because dulaglutide itself showed cardiovascular benefit in the REWIND trial. Tirzepatide outperforming an already-beneficial comparator strengthens the case that dual agonism provides additive cardiovascular protection beyond what GLP-1 alone delivers.

---

Why Does Dual Agonism Work Better?

The SURPASS and SURMOUNT trials demonstrate that tirzepatide outperforms semaglutide. The question of why is still being worked out, but several mechanisms are emerging:

1. Complementary Appetite Pathways

GLP-1 and GIP both reduce appetite, but through partially different brain circuits. GLP-1 acts heavily through the brainstem (area postrema and nucleus tractus solitarius) — which is also why it causes nausea. GIP acts more through the hypothalamus and, via GABAergic neurons, may reduce appetite through a pathway that’s less nausea-inducing. Activating both systems may produce greater appetite suppression with a more tolerable side effect profile than pushing GLP-1 alone to higher levels.[3]

2. Improved Insulin Dynamics

Both hormones are glucose-dependent insulinotropic agents, but they enhance different aspects of insulin secretion. GLP-1 primarily amplifies the “first phase” insulin response (the rapid spike after eating). GIP augments both phases and, importantly, accounts for a larger overall share of the incretin effect. Together, they may restore more normal insulin patterns than either hormone alone — particularly relevant in Type 2 diabetes.[2]

3. Effects on Adipose Tissue

GIP receptor signaling in fat cells influences lipid metabolism, energy expenditure, and adipose tissue blood flow. While the exact mechanism is debated (agonism vs. desensitization-mediated functional antagonism — see the GIP Paradox section above), the net effect appears to enhance fat utilization and improve metabolic health markers in ways that GLP-1 alone doesn’t fully achieve.[4]

4. Synergy, Not Just Addition

Research published in Frontiers in Endocrinology and elsewhere suggests that the GLP-1 and GIP systems interact synergistically — the combined effect is greater than what you’d predict by simply adding each system’s individual contribution. This may involve cross-talk between receptor signaling pathways, complementary effects on different cell populations, or interaction effects in brain circuits that regulate energy balance.[8]

---

The Pipeline: What's Coming Next

If dual agonism outperforms single agonism, would triple agonism be even better? That’s exactly what the next generation of molecules is testing.

Retatrutide (Eli Lilly) — Triple Agonist

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist currently in Phase 3 clinical trials. By adding glucagon receptor activation to the dual GLP-1/GIP platform, it targets an additional metabolic pathway.

Why glucagon? Glucagon is traditionally thought of as the “opposite” of insulin — it raises blood sugar by promoting glucose release from the liver. But glucagon receptors also increase energy expenditure, promote fat breakdown (lipolysis), and may reduce liver fat independently of weight loss.

Phase 2 results (published in NEJM, 2023): In a 48-week trial in adults with obesity, the highest dose of retatrutide produced 24.2% mean body weight loss. At that dose, 100% of patients lost at least 5% of their body weight, 93% lost at least 10%, and 83% lost at least 15%. These numbers exceeded anything previously seen in a Phase 2 obesity trial.[9]

Phase 3 trials have reported up to 26% weight loss, though with some emergence of new safety signals that warrant monitoring. Retatrutide is expected to be a pivotal test of whether adding a third receptor target delivers clinically meaningful improvements over the dual-agonist approach.

Amycretin (Novo Nordisk) — GLP-1/Amylin Dual Agonist

Amycretin takes a different approach to dual agonism. Instead of combining GLP-1 with GIP, it combines GLP-1 with amylin — a hormone co-secreted with insulin by pancreatic beta cells that reduces appetite, slows gastric emptying, and suppresses glucagon.

Phase 2 results (November 2025): Novo Nordisk reported significant weight loss and HbA1c reductions in patients with Type 2 diabetes. The company has advanced amycretin to Phase 3 trials in both obesity and diabetes. Early data suggest it could be competitive with tirzepatide, potentially offering Novo Nordisk a next-generation weapon to compete with Lilly’s dual-agonist platform.[10]

Orforglipron (Eli Lilly) — Oral Non-Peptide GLP-1 Agonist

While not a multi-agonist, orforglipron represents a different kind of breakthrough: it’s a small-molecule, oral GLP-1 agonist — not a peptide. Unlike oral semaglutide (Rybelsus, Wegovy pill), which requires the SNAC absorption enhancer and a strict fasting protocol, orforglipron is a conventional pill that doesn’t have those restrictions.

Phase 3 results announced in 2025 showed that orforglipron helped patients maintain weight loss after switching from injectable GLP-1 therapy — a significant practical advantage. If approved, it could eliminate the barriers of both injections and the rigid fasting protocol required by current oral semaglutide.[11]

CagriSema (Novo Nordisk) — GLP-1 + Amylin (Fixed-Dose Combination)

CagriSema combines semaglutide (the GLP-1 agonist in Ozempic/Wegovy) with cagrilintide (a long-acting amylin analogue) in a single weekly injection. Phase 3 results showed approximately 22-24% weight loss — superior to semaglutide alone — positioning it as Novo Nordisk’s answer to tirzepatide.

---

What This Means for You

If you’re reading this page, you’re probably trying to understand why your provider recommended one medication over another, or why the newer medications seem to work so much better.

The key takeaway: the era of single-receptor medications isn’t ending, but it’s being supplemented by an increasingly sophisticated multi-receptor approach. Semaglutide is still an excellent medication — it changed millions of lives. Tirzepatide builds on that foundation by engaging a second hormonal system. And the next generation of molecules will push even further.

For now, the practical landscape looks like this:

The direction is clear: multi-target approaches are the future of metabolic medicine. The question isn’t whether they’ll arrive — it’s how quickly, and at what cost and accessibility.

---